Trial reportWorld journal of gastroenterology2006
Rectal nitric oxide as biomarker in the treatment of inflammatory bowel disease: responders versus nonresponders.
Trial report in World journal of gastroenterology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 67 citations in OpenAlex.
- Nitric Oxide in the Intestinal Stem Cell Niche: A Spatial Model of Nitrosative Stress and Clonal Evolution in Colitis-Associated Colorectal Cancer.Digestive diseases and sciences · 2026Review
- From Cytokines to Biomarkers: Mapping the Immunopathology of Inflammatory Bowel Disease.Cells · 2025Review
- High iNOS and IL-1β immunoreactivity are features of colitis-associated colorectal cancer tumors, but fail to predict 5-year survival.Upsala journal of medical sciences · 2023Article
- Powering Implantable and Ingestible Electronics.Advanced functional materials · 2021Article
- The Anti-Inflammatory Effect ofEvidence-based complementary and alternative medicine : eCAM · 2021Article
- Altered Caecal Neuroimmune Interactions in the Neuroligin-3Frontiers in cellular neuroscience · 2020Article
- Palm Kernel Cake Oligosaccharides Acute Toxicity and Effects on Nitric Oxide Levels Using a Zebrafish Larvae Model.Frontiers in physiology · 2020Article
- Neurochemistry of Enteric Neurons Following Prolonged Indomethacin Administration in the Porcine Duodenum.Frontiers in pharmacology · 2020Article
- Tendril extract ofInternational journal of medical sciences · 2020Article
- Article
- Anti-inflammatory activity of Jefea gnaphalioides (a. gray), Astereaceae.BMC complementary and alternative medicine · 2019Article
- Nitrergic Enteric Neurons in Health and Disease-Focus on Animal Models.International journal of molecular sciences · 2019Review
- Treatment of inflammatory bowel disease via green tea polyphenols: possible application and protective approaches.Inflammopharmacology · 2018Review
- Polymorphisms in oxidative pathway related genes and susceptibility to inflammatory bowel disease.World journal of gastroenterology · 2017Article
- Anti-inflammatory effect and mechanism of action ofEXCLI journal · 2017Article
- Molecular Alterations of Colorectal Cancer with Inflammatory Bowel Disease.Digestive diseases and sciences · 2015Review
- Review article: the role of oxidative stress in pathogenesis and treatment of inflammatory bowel diseases.Naunyn-Schmiedeberg's archives of pharmacology · 2014Review
- Anti-inflammatory Effect of Oyster Shell Extract in LPS-stimulated Raw 264.7 Cells.Preventive nutrition and food science · 2013Article
- Intestinal myofibroblasts produce nitric oxide in response to combinatorial cytokine stimulation.Journal of cellular physiology · 2013Article
- Nitric oxide as a potential biomarker in inflammatory bowel disease.Bosnian journal of basic medical sciences · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo explore rectal nitric oxide (NO) as biomarker of treatment response in ulcerative colitis (UC) and Crohn's disease (CD), and examine relationships between rectal NO, mucosal expression of NO synthases (NOS), and pro-inflammatory cytokines.
methodsTwenty-two patients with UC and 24 with CD were monitored during steroid treatment. Rectal NO levels were measured and clinical activities were assessed on days 1, 3, 7 and 28. Mucosal presence of NOS and pro-inflammatory cytokines were analyzed by immunohistochemistry and RT-PCR.
resultsActive UC and CD displayed markedly increased rectal NO levels (10950 +/- 7610 and 5040 +/- 1280 parts per billion (ppb), respectively) as compared with the controls (154 +/- 71 ppb, P < 0.001). Rectal NO correlated weakly with disease activity in both UC and CD (r = 0.34 for UC and r = 0.48 for CD, P < 0.01). In 12 patients, a steroid-refractory course led to colectomy. These patients had only slightly increased NO levels (UC: 620 +/- 270 ppb; CD: 1260 +/- 550 ppb) compared to those with a therapeutic response (UC: 18860 +/- 530 ppb, P < 0.001; CD: 10060 +/- 3200 ppb, P < 0.05).
conclusionRectal NO level is a useful biomarker of treatment response in IBD as low NO levels predicts a poor clinical response to steroid treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.